Product Information
MORPHINE SULF ER 30 MG TABLET is a generic product labeled by SpecGx LLC, priced at $0.4413 per EA under NDC 00406833001. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 31, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
30 mg/1
Manufacturer
SpecGx LLCNDC
00406833001
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MORPHINE SULFATEApproval Type
Generic (ANDA)
FDA Application
ANDA076412FDA Approved
7/31/2003
TE Code
AB
On Market Since
7/31/2003
Pharmacological Classes
Price Statistics
The NADAC for MORPHINE SULF ER 30 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 42.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.4413 per EA |
|---|---|
| All-time high | $0.9728 (Mar 12, 2014) |
| All-time low | $0.2713 (Nov 20, 2019) |
| 52-week high | $0.4555 |
| 52-week low | $0.3632 |
| Median price | $0.3800 |
| Average price | $0.4743 |
| Largest weekly change | +27.0% (Jan 22, 2020) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 23% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
SpecGx LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
MORPHINE SULFATE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Opioid Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MORPHINE SULF ER 30 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MORPHINE SULF ER 30 MG TABLET, manufactured by SpecGx LLC, is $0.4413 per EA (NDC 00406833001), effective Sep 30, 2026.
How has the price of MORPHINE SULF ER 30 MG TABLET changed over time?
Over the history we have for it, the NADAC for MORPHINE SULF ER 30 MG TABLET has declined 42.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MORPHINE SULF ER 30 MG TABLET?
Since Nov 28, 2013, the NADAC for MORPHINE SULF ER 30 MG TABLET has ranged from a low of $0.2713 (Nov 20, 2019) to a high of $0.9728 (Mar 12, 2014), with a median of $0.3800 per EA.
Are there cheaper alternatives to MORPHINE SULF ER 30 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MORPHINE SULFATE IR 30 MG TAB, is $0.3414 per EA — about 23% below MORPHINE SULF ER 30 MG TABLET.
Who manufactures MORPHINE SULF ER 30 MG TABLET?
MORPHINE SULF ER 30 MG TABLET (NDC 00406833001) is labeled by SpecGx LLC, and CMS classifies it as a generic product.